سالفينورين أ
مراجع

↑  salvinorin A، PubChem، مؤرشف من الأصل في 2014-10-16، اطلع عليه بتاريخ 2012-11-23
1 2  MacLean، Katherine؛ Johnson، Matthew؛ Reissig، Chad؛ Prisinzano، Thomas؛ Griffiths، Roland (مارس 2013). "Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects". Psychopharmacology. ج. 226 ع. 2: 381–392. DOI:10.1007/s00213-012-2912-9. PMC:3581702. PMID:23135605.
↑  Marushia، Robin (2002). "Salvia divinorum: The Botany, Ethnobotany, Biochemistry and Future of a Mexican Mint" (PDF). Ethnobotany. مؤرشف من الأصل (PDF) في 2007-10-07. اطلع عليه بتاريخ 2006-12-23.
↑  Note: the Mowry et al. study used the following data: 1600 μg/kg (0.0016 mg/g) daily injections for 14 days on "Swiss-Webster mice, aged 4–6 months" of unknown weight (when purchasing mice, an estimated maximum mass is 25 g). Given that the average weight for males in the United States is 190.9 lbs (according to Wikipedia), or 86,590.7834 g, and that a single gram mixture of plain leaf contains roughly 3 mg/g of Salvinorin A (according to Daniel Siebert  ‏), this translates to the mice receiving an effective dose of roughly 6,494,309 times more than a human (human doses range from minimal, 200 μg, to upwards of 24 mg, and body weights for both humans and mice vary tremendously).
↑  Linda P. Dwoskin (29 يناير 2014). Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse. Elsevier Science. ص. 483–. ISBN:978-0-12-420177-4. مؤرشف من الأصل في 2019-12-07.
1 2  Rao S. Rapaka؛ Wolfgang Sadée (19 يونيو 2008). Drug Addiction: From Basic Research to Therapy. Springer Science & Business Media. ص. 236–. ISBN:978-0-387-76678-2. مؤرشف من الأصل في 2019-12-07.
1 2  Parker L. Mott (2 ديسمبر 2011). A Literature Review on the Status and Effects of Salvia Divinorum on Cognitive, Affective, and Behavioral Functioning. Universal-Publishers. ص. 27–. ISBN:978-1-61233-777-7. مؤرشف من الأصل في 2019-12-07.
↑  José Biller (2008). The Interface of Neurology & Internal Medicine. Lippincott Williams & Wilkins. ص. 681–. ISBN:978-0-7817-7906-7. مؤرشف من الأصل في 2016-06-17.
↑  Inan S، Lee DY، Liu-Chen LY، Cowan A (2009). "Comparison of the diuretic effects of chemically diverse kappa opioid agonists in rats: nalfurafine, U50,488H, and salvinorin A". Naunyn Schmiedebergs Arch. Pharmacol. ج. 379 ع. 3: 263–70. DOI:10.1007/s00210-008-0358-8. PMID:18925386.
↑  "Salvia divinorum". European Monitoring Centre for Drugs and Drug Addiction. مؤرشف من الأصل في 2018-08-06. اطلع عليه بتاريخ 2014-09-04. Salvinorin A is unstable in basic solutions and is soluble in conventional organic solvents, including acetone, acetonitrile, chloroform, dimethyl sulfoxide and methanol, but is essentially insoluble in hexane and water.
↑  Pelot, Kyle A.; Mitchell, Rod; Kwon, Moonhyuk; Hagelthorn, David M.; Wardman, Jacob F.; Chiang, Angela; Bohlmann, Jörg; Ro, Dae-Kyun; Zerbe, Philipp (1 Mar 2017). "Biosynthesis of the psychotropic plant diterpene salvinorin A: Discovery and characterization of the Salvia divinorum clerodienyl diphosphate synthase". The Plant Journal (بالإنجليزية). 89 (5): 885–897. DOI:10.1111/tpj.13427. ISSN:1365-313X. Archived from the original on 2017-02-27.
↑  Kunkle D (2007). "Leaf glandular trichome (Salvia divinorum)". Dennis Kunkel Microscopy, Inc. مؤرشف من الأصل في 2016-03-03. اطلع عليه بتاريخ 2011-10-14.
↑  Line، N.؛ Burns، A. C.؛ Butler، S. C.؛ Casbohm، J.؛ Forsyth، C. J. (2016). "Total Synthesis of (−)-Salvinorin A". Chem. Eur. J. ج. 22: 17983–17986. DOI:10.1002/chem.201604853.
↑  White K، Robinson JE، Zhu H، وآخرون (2014). "The G-protein biased k-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo". J. Pharmacol. Exp. Ther. ج. 352 ع. 1: 98–109. DOI:10.1124/jpet.114.216820. PMC:4279099. PMID:25320048.
↑  MacLean، K. A.؛ Johnson، M. W.؛ Reissig، C. J.؛ Prisinzano، T. E.؛ Griffiths، R. R. (2012). "Dose-related effects of salvinorin a in humans: Dissociative, hallucinogenic, and memory effects". Psychopharmacology. ج. 226 ع. 2: 381–392. DOI:10.1007/s00213-012-2912-9. PMC:3581702. PMID:23135605.
↑  Masis, Julie (28 فبراير 2007). "Mexican drug gains U.S. following". Reuters. مؤرشف من الأصل في 2017-09-15.
↑  Prisinzano، Thomas؛ Kevin Tidgewell؛ Wayne W. Harding (2005). "k Opioids as potential treatments for stimulant dependence". The AAPS Journal. Springer New York. ج. 7 ع. 3: E592–E599. DOI:10.1208/aapsj070361. ISSN:1550-7416. PMC:2751263. PMID:16353938. مؤرشف من الأصل في 2018-06-01.
↑  Xuei X؛ Dick D؛ Flury-Wetherill L؛ Tian HJ؛ Agrawal A؛ Bierut L؛ Goate A؛ Bucholz K؛ Schuckit M؛ Nurnberger J Jr؛ Tischfield J؛ Kuperman S؛ Porjesz B؛ Begleiter H؛ Foroud T؛ Edenberg HJ (نوفمبر 2006). "Association of the kappa-opioid system with alcohol dependence". Molecular Psychiatry. ج. 11 ع. 11: 1016–24. DOI:10.1038/sj.mp.4001882. PMID:16924269.
↑  Fichna، Jakub؛ Dicay، Michael؛ Lewellyn، Kevin؛ Janecka، Anna؛ Zjawiony، Jordan K.؛ MacNaughton، Wallace K.؛ Storr، Martin A. (1 يونيو 2012). "Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors". Inflammatory Bowel Diseases. ج. 18 ع. 6: 1137–1145. DOI:10.1002/ibd.21873. ISSN:1536-4844. PMID:21953882.
↑  21 CFR — SCHEDULES OF CONTROLLED SUBSTANCES §1308.11 Schedule I. نسخة محفوظة 16 يوليو 2017 على موقع واي باك مشين.
↑  Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL نسخة محفوظة 01 ديسمبر 2017 على موقع واي باك مشين.
1 2  Poisons Standard October 2015 https://www.comlaw.gov.au/Details/F2015L01534 نسخة محفوظة 8 مارس 2021 على موقع واي باك مشين.
↑  "Wayback Machine" (PDF). مؤرشف من الأصل (PDF) في 2013-09-29.
Roth BL؛ Baner K؛ Westkaemper R؛ Siebert D؛ Rice KC؛ Steinberg S؛ Ernsberger P؛ Rothman RB (2002). "Salvinorin A: a potent naturally occurring nonnitrogenous κ opioid selective agonist". Proceedings of the National Academy of Sciences of the United States of America. ج. 99 ع. 18: 11934–9. DOI:10.1073/pnas.182234399. PMC:129372. PMID:12192085.
Ortega A؛ Blount JF؛ Manchard PD. (1982). "Salvinorin, a new trans-neoclerodane diterpene from Salvia divinorum (Labiatae)". Journal of the Chemical Society, Perkins Transactions I: 2505–8. DOI:10.1039/P19820002505.
Prisinzano TE (2005). "Psychopharmacology of the hallucinogenic sage Salvia divinorum". Life Sciences. ج. 78 ع. 5: 527–31. DOI:10.1016/j.lfs.2005.09.008. PMID:16213533.
Harding WW؛ Schmidt M؛ Tidgewell K؛ Kannan P؛ Holden KG؛ Gilmour B؛ Navarro H؛ Rothman RB؛ Prisinzano TE (2006). "Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A". Journal of Natural Products. ج. 69 ع. 1: 107–12. DOI:10.1021/np050398i. PMC:2544632. PMID:16441078.
Greiner T؛ Burch NR؛ Edelberg R (1958). "Psychopathology and psychophysiology of minimal LSD-25 dosage; a preliminary dosage-response spectrum". AMA Archives of Neurology and Psychiatry. ج. 79 ع. 2: 208–10. DOI:10.1001/archneurpsyc.1958.02340020088016. PMID:13497365.
Lee D؛ Ma Z؛ Liu-Chen L؛ Wang Y؛ Chen Y؛ Carlezon W؛ Cohen B. (2005). "New neoclerodane diterpenoids isolated from the leaves of Salvia divinorum and their binding affinities for human K opioid receptors". Bioorganic and Medicinal Chemistry. ج. 13 ع. 19: 5635–9. DOI:10.1016/j.bmc.2005.05.054. PMID:16084728.
Mowry M؛ Mosher M؛ Briner W (2003). "Acute physiologic and chronic histologic changes in rats and mice exposed to the unique hallucinogen salvinorin A" (PDF). Journal of Psychoactive Drugs. ج. 35 ع. 3: 379–82. DOI:10.1080/02791072.2003.10400021. PMID:14621136. مؤرشف من الأصل (PDF) في 2018-03-24.
Capasso R؛ Borrelli F؛ Capasso F؛ Siebert DJ؛ Stewart DJ؛ Zjawiony JK؛ Izzo AA (2006). "The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum". Neurogastroenterology and Motility. ج. 18 ع. 1: 69–75. DOI:10.1111/j.1365-2982.2005.00725.x. PMID:16371085.
Capasso R؛ Borrelli F؛ Zjawiony J؛ Kutrzeba L؛ Aviello G؛ Sarnelli G؛ Capasso F؛ Izzo AA (2007). "The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A reduce inflammation-induced hypermotility in mice". Neurogastroenterology and Motility. ج. 20 ع. 2: 142–8. DOI:10.1111/j.1365-2982.2007.00994.x. PMID:17931335.
Pichini S؛ Abanades S؛ Farré M؛ Pellegrini M؛ Marchei E؛ Pacifici R؛ Torre Rde L؛ Zuccaro P (2005). "Quantification of the plant-derived hallucinogen salvinorin A in conventional and non-conventional biological fluids by gas chromatography/mass spectrometry after Salvia divinorum smoking". Rapid Communications in Mass Spectrometry. ج. 19 ع. 12: 1649–1656. DOI:10.1002/rcm.1970. ISSN:1097-0231. PMID:15915477. Salvinorin A was not detected in urine samples collected from 1.5–9.5 h after smoking, probably because of a dilution effect, which yielded concentrations below the LOD obtainable with this methodology.
Bigham AK؛ Munro TA؛ Rizzacasa MA؛ Robins-Browne RM (2003). "Divinatorins A-C, new neoclerodane diterpenoids from the controlled sage Salvia divinorum". Journal of Natural Products. ج. 66 ع. 9: 1242–4. DOI:10.1021/np030313i. PMID:14510607.
Munro TA؛ Rizzacasa MA (2003). "Salvinorins D-F, new neoclerodane diterpenoids from Salvia divinorum, and an improved method for the isolation of salvinorin A". Journal of Natural Products. ج. 66 ع. 5: 703–5. DOI:10.1021/np0205699. PMID:12762813.
Kutrzeba L؛ Dayan FE؛ Howell J؛ Feng J؛ Giner JL؛ Zjawiony JK (2007). "Biosynthesis of salvinorin A proceeds via the deoxyxylulose phosphate pathway". Phytochemistry. ج. 68 ع. 14: 1872–81. DOI:10.1016/j.phytochem.2007.04.034. PMC:2065853. PMID:17574635.
Scheerer JR؛ Lawrence JF؛ Wang GC؛ Evans DA (2007). "Asymmetric synthesis of salvinorin A, a potent kappa opioid receptor agonist". Journal of the American Chemical Society. ج. 129 ع. 29: 8968–9. DOI:10.1021/ja073590a. PMID:17602636.
Nozawa M؛ Suka Y؛ Hoshi T؛ Suzuki T؛ Hagiwara H (2008). "Total synthesis of the hallucinogenic neoclerodane diterpenoid salvinorin A". Organic Letters. ج. 10 ع. 7: 1365–8. DOI:10.1021/ol800101v. PMID:18311991.
Burns AC؛ Forsyth CJ. (2008). "Intramolecular Diels−Alder/Tsuji allylation assembly of the functionalized trans-decalin of salvinorin A". Organic Letters. ج. 10 ع. 1: 97–100. DOI:10.1021/ol7024058. PMID:18062692.
Lingham AR؛ Hügel HM؛ Rook TJ (2006). "Studies towards the synthesis of salvinorin A". Australian Journal of Chemistry. ج. 59 ع. 5: 340–8. DOI:10.1071/CH05338.
Kutrzeba L؛ Ferreira Z (2009). "Salvinorins J from Salvia divinorum: mutarotation in the neoclerodane system". Journal of Natural Products. ج. 72 ع. 7: 1361–3. DOI:10.1021/np900181q. PMID:19473009.
Lee DY؛ Karnati VV؛ He M؛ Liu-Chen LY؛ Kondaveti L؛ Ma Z؛ Wang Y؛ Chen Y؛ Beguin C؛ Carlezon WA؛ Cohen B (2005). "Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues". Bioorganic & Medicinal Chemistry Letters. ج. 15 ع. 16: 3744–7. DOI:10.1016/j.bmcl.2005.05.048. PMID:15993589.
Munro TA؛ Duncan KK؛ Xu W؛ Wang Y؛ Liu-Chen LY؛ Carlezon WA؛ Cohen BM؛ Béguin C (2008). "Standard protecting groups create potent and selective κ opioids: salvinorin B alkoxymethyl ethers". Bioorganic & Medicinal Chemistry. ج. 16 ع. 3: 1279–86. DOI:10.1016/j.bmc.2007.10.067. PMC:2568987. PMID:17981041.
Harding WW؛ Tidgewell K؛ Byrd N؛ Cobb H؛ Dersch CM؛ Butelman ER؛ Rothman RB؛ Prisinzano TE (2005). "Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands". Journal of Medicinal Chemistry. ج. 48 ع. 15: 4765–71. DOI:10.1021/jm048963m. PMID:16033256.
Holden KG؛ Tidgewell K؛ Marquam A؛ Rothman RB؛ Navarro H؛ Prisinzano TE (2007). "Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position". Bioorganic and Medicinal Chemistry Letters. ج. 17 ع. 22: 6111–5. DOI:10.1016/j.bmcl.2007.09.050. PMC:2111044. PMID:17904842.
Lee DY؛ He M؛ Liu-Chen LY؛ Wang Y؛ Li JG؛ Xu W؛ Ma Z؛ Carlezon WA؛ Cohen B (2006). "Synthesis and in vitro pharmacological studies of new C(4)-modified salvinorin A analogues". Bioorganic & Medicinal Chemistry Letters. ج. 16 ع. 21: 5498–502. DOI:10.1016/j.bmcl.2006.08.051. PMID:16945525.
Béguin C؛ Richards MR؛ Li JG؛ Wang Y؛ Xu W؛ Liu-Chen LY؛ Carlezon WA؛ Cohen BM (2006). "Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18)". Bioorganic & Medicinal Chemistry Letters. ج. 16 ع. 17: 4679–85. DOI:10.1016/j.bmcl.2006.05.093. PMID:16777411.
A1 US 2007/0213394 A1, Beguin C, Carlezon WA, Cohen BM, He M, Lee D Y-W, Richards MR, Liu-Chen L-Y, "Salvinorin derivatives and uses thereof", published 2007-09-13,  assigned to Temple University
Imanshahidi M؛ Hosseinzadeh H (2006). "The pharmacological effects of Salvia species on the central nervous system". Phytotherapy Research. ج. 20 ع. 6: 427–37. DOI:10.1002/ptr.1898. PMID:16619340. However, when smoked (in a manner similar to free base cocaine), the compound is effective in doses of 200–500 μg and produces visions that last from 30 minutes to an hour or two, while doses over 2 mg are effective for much longer. At doses greater than 500 μg the subject is often no longer aware of their surroundings and may enter an uncontrollable delirium. This compound is the most potent naturally occurring hallucinogen thus far isolated.
Seeman P؛ Guan HC؛ Hirbec H (2009). "Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil". Synapse. ج. 63 ع. 8: 698–704. DOI:10.1002/syn.20647. PMID:19391150.
Siebert DJ (2004). "Localization of salvinorin A and related compounds in glandular trichomes of the psychoactive sage, Salvia divinorum". Annals of Botany. ج. 93 ع. 6: 763–71. DOI:10.1093/aob/mch089. PMID:15087301. "A peltate glandular trichome on the abaxial leaf surface", and "The fact that most of the salvinorin content of fresh leaves can be extracted into chloroform without the solvent penetrating the epidermis indicates that these compounds are secreted externally to the epidermis."
Tidgewell K؛ Harding WW؛ Lozama A؛ Cobb H؛ Shah K؛ Kannan P؛ Dersch CM؛ Parrish D؛ Deschamps JR؛ Rothman RB؛ Prisinzano TE (2006). "Synthesis of salvinorin A analogues as opioid receptor probes". Journal of Natural Products. ج. 69 ع. 6: 914–8. DOI:10.1021/np060094b. PMID:16792410.
Valdés LJJ III (1983). The pharmacognosy of Salvia divinorum (Epling and Jativa-M): An Investigation of Ska Maria Pastora (Mexico) (PhD thesis). University of Michigan. مؤرشف من الأصل في 2015-10-16.
Valdés III LJJ؛ Butler WM؛ Hatfield GM؛ Paul AG؛ Koreeda M. (1984). "Divinorin A, a psychotropic terpenoid, and divinorin B from the hallucinogenic Mexican mint Salvia divinorum". Journal of Organic Chemistry. ج. 49 ع. 24: 4716–20. DOI:10.1021/jo00198a026.
Valdés III LJJ؛ Chang HM؛ Visger DC؛ Koreeda M. (2001). "Salvinorin C, a new neoclerodane diterpene from a bioactive fraction of the hallucinogenic Mexican mint Salvia divinorum". Organic Letters. ج. 3 ع. 24: 3935–7. DOI:10.1021/ol016820d. PMID:11720573.
Zhang Y؛ Butelman ER؛ Schlussman SD؛ Ho A؛ Kreek MJ (2005). "Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors". Psychopharmacology (Berl.). ج. 179 ع. 3: 551–8. DOI:10.1007/s00213-004-2087-0. PMID:15682306.